Pathway Capital Management, LP Mersana Therapeutics, Inc. Call Options Transaction History
Pathway Capital Management, LP
- $26.7 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MRSN
# of Institutions
85Shares Held
94.1MCall Options Held
34.3KPut Options Held
14K-
Nextech Invest Ag12.1MShares$125 Million3.22% of portfolio
-
Nextech Invest, Ltd. Zurich, V812.1MShares$125 Million0.68% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$89.9 Million0.78% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$87 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.68MShares$79.7 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $1.01B
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...